Glenmark
A new way for a new world

March 01, 2012

The Manager
Listing Dept,
The National Stock Exchange of India Ltd
Plot No. C/1,G Block
Bandra Kurla Complex
Bandra (E) Mumbai-400051

Dear Sir,

We are enclosing herewith a press release informing "**Glenmark Generics receives ANDA approvals for Ciclopirox Gel 0.77% and Levonorgestrel & Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg**", for your information and record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.

Marshall Mendonza
Vice President & Company Secretary

Tel: 4018 9999 / 4018 9879
Fax No: 4018 9986 (Legal & Secretarial Dept.)
Encl: as above

Glenmark Generics Ltd.

glenmark
A new way for a new world

Press Release For Immediate Release

Glenmark Generics receives ANDA approvals for Ciclopirox Gel 0.77% and Levonorgestrel & Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg

Mar 1, 2012: Glenmark Generics Inc., USA the subsidiary of Glenmark Generics Limited, today announced they have been granted final approval for two abbreviated new drug approvals (ANDA's) from the United States Food and Drug Administration (U.S. FDA).

Today's approvals are for Ciclopirox Gel 0.77% and Levonorgestrel & Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg. Glenmark will market this approved oral contraceptive as Marlissa™ Tablets and plan to commence shipping both products immediately.

Ciclopirox Gel 0.77%, is the generic version of Loprox® Gel, 0.77%, of Medicis Pharmaceutical Corporation. Ciclopirox Gel is indicated for the topical treatment of seborrheic dermatitis of the scalp and is available in 30, 45, and 100 gram tube presentations. According to IMS Health sales data for the 12 month period ending September 2011, Ciclopirox Gel garnered annual sales of greater than USD 10 million.

Marlissa™ Tablets are Glenmark's generic version of Nordette® tablets by Duramed Pharmaceuticals. Marlissa™ Tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. According to IMS Health for the 12 month period ending September 2011 total market sales achieved for Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg were approximately USD 50.84 million. Today's approval marks Glenmark's eight female hormonal product authorized for distribution by the U.S. FDA.

Glenmark's current portfolio consists of 76 products authorized for distribution in the U.S. marketplace. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

About Glenmark Generics Limited.
Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

#####

For further information, please contact:
Jason D'Souza / Rajdeep Barooah
Glenmark, Mumbai, India Tel: [+91 22] 40189919 Email : connect@glenmark-generics.com